Cargando…

Hyperkalemia: pathophysiology, risk factors and consequences

There have been significant recent advances in our understanding of the mechanisms that maintain potassium homoeostasis and the clinical consequences of hyperkalemia. In this article we discuss these advances within a concise review of the pathophysiology, risk factors and consequences of hyperkalem...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunter, Robert W, Bailey, Matthew A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892421/
https://www.ncbi.nlm.nih.gov/pubmed/31800080
http://dx.doi.org/10.1093/ndt/gfz206
_version_ 1783476027274559488
author Hunter, Robert W
Bailey, Matthew A
author_facet Hunter, Robert W
Bailey, Matthew A
author_sort Hunter, Robert W
collection PubMed
description There have been significant recent advances in our understanding of the mechanisms that maintain potassium homoeostasis and the clinical consequences of hyperkalemia. In this article we discuss these advances within a concise review of the pathophysiology, risk factors and consequences of hyperkalemia. We highlight aspects that are of particular relevance for clinical practice. Hyperkalemia occurs when renal potassium excretion is limited by reductions in glomerular filtration rate, tubular flow, distal sodium delivery or the expression of aldosterone-sensitive ion transporters in the distal nephron. Accordingly, the major risk factors for hyperkalemia are renal failure, diabetes mellitus, adrenal disease and the use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or potassium-sparing diuretics. Hyperkalemia is associated with an increased risk of death, and this is only in part explicable by hyperkalemia-induced cardiac arrhythmia. In addition to its well-established effects on cardiac excitability, hyperkalemia could also contribute to peripheral neuropathy and cause renal tubular acidosis. Hyperkalemia—or the fear of hyperkalemia—contributes to the underprescription of potentially beneficial medications, particularly in heart failure. The newer potassium binders could play a role in attempts to minimize reduced prescribing of renin–angiotensin inhibitors and mineraolocorticoid antagonists in this context.
format Online
Article
Text
id pubmed-6892421
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68924212019-12-10 Hyperkalemia: pathophysiology, risk factors and consequences Hunter, Robert W Bailey, Matthew A Nephrol Dial Transplant Reviews There have been significant recent advances in our understanding of the mechanisms that maintain potassium homoeostasis and the clinical consequences of hyperkalemia. In this article we discuss these advances within a concise review of the pathophysiology, risk factors and consequences of hyperkalemia. We highlight aspects that are of particular relevance for clinical practice. Hyperkalemia occurs when renal potassium excretion is limited by reductions in glomerular filtration rate, tubular flow, distal sodium delivery or the expression of aldosterone-sensitive ion transporters in the distal nephron. Accordingly, the major risk factors for hyperkalemia are renal failure, diabetes mellitus, adrenal disease and the use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or potassium-sparing diuretics. Hyperkalemia is associated with an increased risk of death, and this is only in part explicable by hyperkalemia-induced cardiac arrhythmia. In addition to its well-established effects on cardiac excitability, hyperkalemia could also contribute to peripheral neuropathy and cause renal tubular acidosis. Hyperkalemia—or the fear of hyperkalemia—contributes to the underprescription of potentially beneficial medications, particularly in heart failure. The newer potassium binders could play a role in attempts to minimize reduced prescribing of renin–angiotensin inhibitors and mineraolocorticoid antagonists in this context. Oxford University Press 2019-12 2019-12-04 /pmc/articles/PMC6892421/ /pubmed/31800080 http://dx.doi.org/10.1093/ndt/gfz206 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Hunter, Robert W
Bailey, Matthew A
Hyperkalemia: pathophysiology, risk factors and consequences
title Hyperkalemia: pathophysiology, risk factors and consequences
title_full Hyperkalemia: pathophysiology, risk factors and consequences
title_fullStr Hyperkalemia: pathophysiology, risk factors and consequences
title_full_unstemmed Hyperkalemia: pathophysiology, risk factors and consequences
title_short Hyperkalemia: pathophysiology, risk factors and consequences
title_sort hyperkalemia: pathophysiology, risk factors and consequences
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892421/
https://www.ncbi.nlm.nih.gov/pubmed/31800080
http://dx.doi.org/10.1093/ndt/gfz206
work_keys_str_mv AT hunterrobertw hyperkalemiapathophysiologyriskfactorsandconsequences
AT baileymatthewa hyperkalemiapathophysiologyriskfactorsandconsequences